Fat Loss & Metabolism

01 Modest weight loss

• Modest weight loss: meta-analysis of 37 RCTs (2,292 people) found ~1.2 kg more weight loss, BMI -0.24, fat mass -2.08 kg vs control; earlier 9-RCT meta-analysis ~1.3 kghuman RCT meta-analyses12

01 About 15% weight loss

• Weight loss: STEP 1 (68 wk) mean 14.9% vs 2.4% placebo with 2.4 mg weeklyhuman phase 3 RCT34

01 Leaner body composition

• Improves body composition: in GH-deficient adults increases lean mass (~1.4-2.6 kg) and reduces fat mass (~2.2-2.6 kg) vs placebometa-analyses of human RCTs567

03 Less visceral fat, better lipids

• Reduces visceral fat and improves lipids (total/LDL cholesterol) in obese adults without GHD, but no net weight lossmeta-analysis of RCTs
• Long-term (5-15 yr) replacement in GHD adults linked to sustained quality-of-life gains (mostly uncontrolled studies)

Sources for this benefit 8910

01 Less deep belly fat

• Reduces visceral adipose tissue (deep belly fat) with little change in subcutaneous fatFDA label; pooled phase 3 RCTs in HIV111213

01 Major weight loss

• Weight loss: 20.9% mean at 72 weeks on 15 mg vs 3.1% placeboSURMOUNT-1 phase 3 RCT1415

02 Blood sugar and heart risk

• Glycemic control in type 2 diabetes and cardiovascular event reduction in high-risk adultsFDA label, SURPASS program1617

01 Fat loss, failed in trials

• Fat loss (intended): early trials suggested modest weight/abdominal fat loss, but the definitive 536-person 24-week Phase IIb trial showed no significant weight loss vs placebo and obesity development was terminatedhuman RCT, negative181920

01 Weight loss

• Weight loss: phase 2 (n=706, 26 wk) dose-dependent loss of 6.0-10.8% vs 3.0% placebo; 4.5 mg (10.8%) beat liraglutide 3.0 mg (9.0%)human RCT2122

02 Bigger results with semaglutide

• With semaglutide (CagriSema): REDEFINE 1 phase 3 (n=3,417, 68 wk) mean weight loss 20.4% vs 3.0% placebo; 34.7% lost >=25%; mostly fat mass losthuman phase 3 RCT2324

03 Quieter food noise

• Reduced 'food noise' and appetite (CagriSema EASD 2026 data; Reddit users describe strong appetite suppression at varying doses)human trial + anecdotal2526

01 Large weight loss

• Large weight loss: 24.2% mean at 48 weeks on 12 mg vs 2.1% placebo (phase 2 RCT); 25.0% at 80 weeks on 12 mg vs 3.9% placebo in phase 3 TRIUMPH-1272829

02 Blood sugar control

• Glycemic control in type 2 diabetes: HbA1c -1.3% to -2.0% at 24 weeks with up to ~17% weight loss at 36 weeksphase 2 RCT3031

02 Visceral fat, trial halted

• Was tested for reducing visceral fat in HIV lipodystrophy (phase 2, n=192), but trial halted, no efficacy publishedhuman trial, stopped4647

03 Sleep, muscle and fat, unproven claims

• Claimed sleep, muscle and abdominal fat-loss benefits are extrapolated from GH/IGF-1 elevation and GHRH research; no dedicated CJC-1295 outcome studiespractitioner/vendor review48

02 Less neuropathic pain

• Improved neuropathic pain (PainDetect) and modestly lowered HbA1c in type 2 diabetics with painful neuropathyphase 2 human RCT, n=424950

03 Appetite suppression, animal

• Appetite suppression via central melanocortin receptorsanimal studies; user reports of reduced appetite5253

01 Fat loss, mice

• Fat loss: in diet-induced obese mice, 11 days of injections cut body weight ~5.1% (controls gained 1.4%), reduced white fat mass ~35% and adipocyte size, and lowered cholesterol ~30% without changing food intakeanimal32

03 Metabolic health, mice

• Obesity-related metabolic dysfunction improved with NNMT inhibition in miceanimal, 202433
• Users report modest fat loss, less hunger or alertness; others nothinganecdotal/Reddit3435

01 Insulin sensitivity, animal

• Improves insulin sensitivity and glucose uptake in skeletal muscle and prevented diet-induced obesity and insulin resistance in miceanimal study3637

03 Body composition, anecdotal

• Body composition/recovery changes reported by users after ~8-12 weeks, usually stacked with ipamorelinanecdotal/Reddit54

03 Sleep and body composition, anecdotal

• Sleep quality and body composition: users frequently report deeper sleep and, after 8-12 weeks, recompositionanecdotal/Reddit5556

01 Fat burning, unproven

• Marketed for fat loss/'fat burning', but no randomized trials of the MIC combination show weight loss beyond diet/exercise; FDA has sent warning letters over unsubstantiated weight-loss claimspractitioner/pharmacy review; no RCTs3839

01 Spot fat reduction, unproven

• Marketed for spot fat reduction/body contouring; no published clinical trials found supporting efficacyregulator/professional warnings; no data4041

01 Fat metabolism, unproven

• Marketed to boost fat metabolism and weight loss, but no meaningful added weight loss shown beyond diet in controlled studiesreview/clinic blogs394243

03 Insulin sensitivity, inositol data

• Inositol (myo-inositol) may lower fasting insulin/HOMA-IR in PCOSmeta-analyses of RCTs, heterogeneous evidence; oral doses, not MIC shots4445

02 Belly fat, via tesamorelin

• See Tesamorelin: visceral fat reduction (FDA-approved in HIV), liver fat and cognition datahuman RCTs1251

03 Body recomposition, anecdotal

• Body composition/recovery changes reported around 8-12 weeks, sometimes with lab IGF-1 data posted by usersanecdotal5457